Indwelling pleural catheter enabling safe air travel in malignant pleural effusion with pneumothorax ex vacuo.

BMJ Case RepSep 5, 2026 (epub)
Case ReportOncology (Medical)Pulmonology

Foley Lachal, Maureen Goodwin, Sanjeevan Muruganandan et al.

✦ AI-curated · Sources linked

Case in brief

A man with pleural mesothelioma developed a large left hydropneumothorax after drainage of malignant pleural effusion. An indwelling pleural catheter was placed, allowing for management of symptoms and the risk of air expansion during a domestic flight. This approach enabled the patient to travel safely with his family, fulfilling a significant personal wish.

Diagnostic / clinical pearl

In selected patients with malignant pleural effusion and pneumothorax ex vacuo, the use of an indwelling pleural catheter may facilitate safe air travel.

Source

PubMed · PMID 42700971

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.